JP2014506590A5 - - Google Patents

Download PDF

Info

Publication number: JP2014506590A5
Authority: JP; Japan
Prior art keywords: alkyl; optionally substituted; group; methyl; alkynyl
Prior art date: 2012-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2013554966A

Other languages

English (en)

Japanese (ja)

Other versions

JP6118270B2 (ja

JP2014506590A (ja

Filing date

2012-02-22

Publication date

2015-04-09

2012-02-22 Application filed filed Critical

2012-02-22 Priority claimed from PCT/IB2012/050806 external-priority patent/WO2012114285A1/en

2014-03-17 Publication of JP2014506590A publication Critical patent/JP2014506590A/ja

2015-04-09 Publication of JP2014506590A5 publication Critical patent/JP2014506590A5/ja

2017-04-19 Application granted granted Critical

2017-04-19 Publication of JP6118270B2 publication Critical patent/JP6118270B2/ja

Status Active legal-status Critical Current

2032-02-22 Anticipated expiration legal-status Critical

Links

125000000217 alkyl group Chemical group 0.000 claims 113
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 103
125000000623 heterocyclic group Chemical group 0.000 claims 50
-1 cyano, hydroxy Chemical group 0.000 claims 38
125000001072 heteroaryl group Chemical group 0.000 claims 37
125000003342 alkenyl group Chemical group 0.000 claims 30
125000000304 alkynyl group Chemical group 0.000 claims 30
150000001875 compounds Chemical class 0.000 claims 25
125000000547 substituted alkyl group Chemical group 0.000 claims 25
125000003118 aryl group Chemical group 0.000 claims 24
229910052736 halogen Inorganic materials 0.000 claims 24
150000002367 halogens Chemical class 0.000 claims 24
229910052739 hydrogen Inorganic materials 0.000 claims 24
239000001257 hydrogen Substances 0.000 claims 24
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 24
125000001424 substituent group Chemical group 0.000 claims 24
125000004093 cyano group Chemical group *C#N 0.000 claims 22
150000002431 hydrogen Chemical class 0.000 claims 21
125000000753 cycloalkyl group Chemical group 0.000 claims 20
125000005346 substituted cycloalkyl group Chemical group 0.000 claims 20
150000003839 salts Chemical class 0.000 claims 19
125000004043 oxo group Chemical group O=* 0.000 claims 18
125000005017 substituted alkenyl group Chemical group 0.000 claims 16
125000004426 substituted alkynyl group Chemical group 0.000 claims 16
125000005842 heteroatom Chemical group 0.000 claims 14
125000004404 heteroalkyl group Chemical group 0.000 claims 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
125000003107 substituted aryl group Chemical group 0.000 claims 12
125000004122 cyclic group Chemical group 0.000 claims 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
229910052757 nitrogen Inorganic materials 0.000 claims 10
229910052717 sulfur Inorganic materials 0.000 claims 9
229910052760 oxygen Inorganic materials 0.000 claims 8
208000010877 cognitive disease Diseases 0.000 claims 7
201000010099 disease Diseases 0.000 claims 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
229920006395 saturated elastomer Polymers 0.000 claims 7
208000028698 Cognitive impairment Diseases 0.000 claims 6
125000004433 nitrogen atom Chemical group N* 0.000 claims 6
239000003814 drug Substances 0.000 claims 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
206010012289 Dementia Diseases 0.000 claims 4
150000001721 carbon Chemical group 0.000 claims 4
208000024827 Alzheimer disease Diseases 0.000 claims 3
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
229910052799 carbon Inorganic materials 0.000 claims 3
208000035475 disorder Diseases 0.000 claims 3
229940079593 drug Drugs 0.000 claims 3
210000000056 organ Anatomy 0.000 claims 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
125000004193 piperazinyl group Chemical group 0.000 claims 3
125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
208000002193 Pain Diseases 0.000 claims 2
208000018737 Parkinson disease Diseases 0.000 claims 2
208000030886 Traumatic Brain injury Diseases 0.000 claims 2
201000004810 Vascular dementia Diseases 0.000 claims 2
210000004204 blood vessel Anatomy 0.000 claims 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
208000026278 immune system disease Diseases 0.000 claims 2
210000004558 lewy body Anatomy 0.000 claims 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
125000003386 piperidinyl group Chemical group 0.000 claims 2
201000000980 schizophrenia Diseases 0.000 claims 2
230000009529 traumatic brain injury Effects 0.000 claims 2
OVXJXUQIGIWHEK-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-4-methyl-3-(4-piperidin-1-ylsulfonylphenyl)thiophen-2-yl]propan-1-one Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C(C=C1)=CC=C1S(=O)(=O)N1CCCCC1 OVXJXUQIGIWHEK-UHFFFAOYSA-N 0.000 claims 1
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
JIXVXTOJWFELIT-UHFFFAOYSA-N 4-[2-acetyl-5-(4-chlorophenyl)-4-methylthiophen-3-yl]benzenesulfonamide Chemical compound CC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 JIXVXTOJWFELIT-UHFFFAOYSA-N 0.000 claims 1
UFFRPOINLQRCOO-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-1,4-dimethyl-2-propanoylpyrrol-3-yl]benzenesulfonamide Chemical compound CN1C(C(=O)CC)=C(C=2C=CC(=CC=2)S(N)(=O)=O)C(C)=C1C1=CC=C(Cl)C=C1 UFFRPOINLQRCOO-UHFFFAOYSA-N 0.000 claims 1
RDOQYOYVSYMZDJ-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-1-ethyl-4-methyl-2-propanoylpyrrol-3-yl]benzenesulfonamide Chemical compound CCN1C(C(=O)CC)=C(C=2C=CC(=CC=2)S(N)(=O)=O)C(C)=C1C1=CC=C(Cl)C=C1 RDOQYOYVSYMZDJ-UHFFFAOYSA-N 0.000 claims 1
YSTWQCSMRHVGPN-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-2-propanoylthiophen-3-yl]benzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=CC=1C1=CC=C(S(N)(=O)=O)C=C1 YSTWQCSMRHVGPN-UHFFFAOYSA-N 0.000 claims 1
UTYKABNJDPLOIC-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-(dimethylamino)-2-propanoylthiophen-3-yl]benzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(N(C)C)C=1C1=CC=C(S(N)(=O)=O)C=C1 UTYKABNJDPLOIC-UHFFFAOYSA-N 0.000 claims 1
DBRXYUZKHRHRMW-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-[(dimethylamino)methyl]-2-propanoylthiophen-3-yl]benzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(CN(C)C)C=1C1=CC=C(S(N)(=O)=O)C=C1 DBRXYUZKHRHRMW-UHFFFAOYSA-N 0.000 claims 1
QEQXBTYYHGIUCK-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-methyl-2-propanoyl-1h-pyrrol-3-yl]benzenesulfonamide Chemical compound CCC(=O)C=1NC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 QEQXBTYYHGIUCK-UHFFFAOYSA-N 0.000 claims 1
RRMNYWQOHCDIOK-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-methyl-2-propanoylthiophen-3-yl]-n,n-dimethylbenzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(=O)(=O)N(C)C)C=C1 RRMNYWQOHCDIOK-UHFFFAOYSA-N 0.000 claims 1
WFNYBPJRPXJGRK-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-methyl-2-propanoylthiophen-3-yl]-n-methylbenzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(=O)(=O)NC)C=C1 WFNYBPJRPXJGRK-UHFFFAOYSA-N 0.000 claims 1
DYIIYIJHDMIABW-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-4-methyl-2-propanoylthiophen-3-yl]benzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 DYIIYIJHDMIABW-UHFFFAOYSA-N 0.000 claims 1
RNMYKOMXUBBUGJ-UHFFFAOYSA-N 4-[5-(4-methoxyphenyl)-4-methyl-2-propanoylthiophen-3-yl]benzenesulfonamide Chemical compound CCC(=O)C=1SC(C=2C=CC(OC)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 RNMYKOMXUBBUGJ-UHFFFAOYSA-N 0.000 claims 1
125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
QOXQGDILIPAINR-UHFFFAOYSA-N 5-(4-chlorophenyl)-n,n,1,4-tetramethyl-3-(4-sulfamoylphenyl)pyrrole-2-carboxamide Chemical compound CN1C(C(=O)N(C)C)=C(C=2C=CC(=CC=2)S(N)(=O)=O)C(C)=C1C1=CC=C(Cl)C=C1 QOXQGDILIPAINR-UHFFFAOYSA-N 0.000 claims 1
VHCJGVRILQNFDJ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n,n,4-trimethyl-3-(4-sulfamoylphenyl)thiophene-2-carboxamide Chemical compound CN(C)C(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 VHCJGVRILQNFDJ-UHFFFAOYSA-N 0.000 claims 1
LGHXVLYSCJRRIB-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2-hydroxyethyl)-4-methyl-n-propyl-3-(4-sulfamoylphenyl)thiophene-2-carboxamide Chemical compound CCCN(CCO)C(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 LGHXVLYSCJRRIB-UHFFFAOYSA-N 0.000 claims 1
YNRLBJJKFSMVFK-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-methoxy-n,4-dimethyl-3-(4-sulfamoylphenyl)thiophene-2-carboxamide Chemical compound CON(C)C(=O)C=1SC(C=2C=CC(Cl)=CC=2)=C(C)C=1C1=CC=C(S(N)(=O)=O)C=C1 YNRLBJJKFSMVFK-UHFFFAOYSA-N 0.000 claims 1
208000030507 AIDS Diseases 0.000 claims 1
206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
208000020925 Bipolar disease Diseases 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
OIBXNTRFHALESR-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=C(C(=C(S1)C(CC)=O)C=1C(=C(C=CC=1)S(=O)(=O)N)C)C Chemical compound ClC1=CC=C(C=C1)C1=C(C(=C(S1)C(CC)=O)C=1C(=C(C=CC=1)S(=O)(=O)N)C)C OIBXNTRFHALESR-UHFFFAOYSA-N 0.000 claims 1
208000015943 Coeliac disease Diseases 0.000 claims 1
206010009900 Colitis ulcerative Diseases 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 claims 1
201000010374 Down Syndrome Diseases 0.000 claims 1
201000011240 Frontotemporal dementia Diseases 0.000 claims 1
208000023105 Huntington disease Diseases 0.000 claims 1
208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
206010065390 Inflammatory pain Diseases 0.000 claims 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
206010033645 Pancreatitis Diseases 0.000 claims 1
208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
208000004550 Postoperative Pain Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
206010039966 Senile dementia Diseases 0.000 claims 1
206010040070 Septic Shock Diseases 0.000 claims 1
206010044248 Toxic shock syndrome Diseases 0.000 claims 1
231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
201000006704 Ulcerative Colitis Diseases 0.000 claims 1
230000001154 acute effect Effects 0.000 claims 1
208000005298 acute pain Diseases 0.000 claims 1
230000033115 angiogenesis Effects 0.000 claims 1
239000000935 antidepressant agent Substances 0.000 claims 1
229940005513 antidepressants Drugs 0.000 claims 1
206010003246 arthritis Diseases 0.000 claims 1
239000003693 atypical antipsychotic agent Substances 0.000 claims 1
229940127236 atypical antipsychotics Drugs 0.000 claims 1
125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 claims 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims 1
229960000074 biopharmaceutical Drugs 0.000 claims 1
239000000544 cholinesterase inhibitor Substances 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
230000019771 cognition Effects 0.000 claims 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
201000003146 cystitis Diseases 0.000 claims 1
230000006735 deficit Effects 0.000 claims 1
VEVOECUDDNJOOR-UHFFFAOYSA-L diethyl-methyl-[2-(1-methyl-1-azoniabicyclo[2.2.2]octane-2-carbonyl)oxyethyl]azanium;diiodide Chemical compound [I-].[I-].C1C[N+]2(C)C(C(=O)OCC[N+](C)(CC)CC)CC1CC2 VEVOECUDDNJOOR-UHFFFAOYSA-L 0.000 claims 1
239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
JIGSWJHMJDWBIL-UHFFFAOYSA-N ethyl 5-(4-chlorophenyl)-4-methyl-3-(4-sulfamoyl-5,6,7,8-tetrahydronaphthalen-1-yl)thiophene-2-carboxylate Chemical compound CC=1C(C=2C=3CCCCC=3C(=CC=2)S(N)(=O)=O)=C(C(=O)OCC)SC=1C1=CC=C(Cl)C=C1 JIGSWJHMJDWBIL-UHFFFAOYSA-N 0.000 claims 1
125000002541 furyl group Chemical group 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
208000015181 infectious disease Diseases 0.000 claims 1
230000002458 infectious effect Effects 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
208000027061 mild cognitive impairment Diseases 0.000 claims 1
125000002757 morpholinyl group Chemical group 0.000 claims 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
208000004296 neuralgia Diseases 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
208000021722 neuropathic pain Diseases 0.000 claims 1
230000004112 neuroprotection Effects 0.000 claims 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
201000001245 periodontitis Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
230000002980 postoperative effect Effects 0.000 claims 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
201000000306 sarcoidosis Diseases 0.000 claims 1
230000001953 sensory effect Effects 0.000 claims 1
230000035939 shock Effects 0.000 claims 1
230000005586 smoking cessation Effects 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
230000029663 wound healing Effects 0.000 claims 1

JP2013554966A 2011-02-23 2012-02-22 アルファ７ｎａｃｈｒモジュレータとしてのヘテロアリール誘導体 Active JP6118270B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
IN242KO2011		2011-02-23
IN242/KOL/2011		2011-02-23
IN1184KO2011		2011-09-09
IN1184/KOL/2011		2011-09-09
PCT/IB2012/050806 WO2012114285A1 (en)	2011-02-23	2012-02-22	Heteroaryl derivatives as alpha7 nachr modulators

Publications (3)

Publication Number	Publication Date
JP2014506590A JP2014506590A (ja)	2014-03-17
JP2014506590A5 true JP2014506590A5 (2)	2015-04-09
JP6118270B2 JP6118270B2 (ja)	2017-04-19

Family

ID=45873193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2013554966A Active JP6118270B2 (ja)	2011-02-23	2012-02-22	アルファ７ｎａｃｈｒモジュレータとしてのヘテロアリール誘導体

Country Status (37)

Country	Link
US (2)	US9072731B2 (2)
EP (1)	EP2678327B9 (2)
JP (1)	JP6118270B2 (2)
KR (1)	KR20140026378A (2)
CN (1)	CN103402994B (2)
AP (1)	AP3649A (2)
AU (1)	AU2012221800B2 (2)
BR (1)	BR112013021602A2 (2)
CA (1)	CA2826792A1 (2)
CL (1)	CL2013002449A1 (2)
CO (1)	CO6761374A2 (2)
CR (1)	CR20130415A (2)
CU (1)	CU24177B1 (2)
CY (1)	CY1118107T1 (2)
DK (1)	DK2678327T3 (2)
DO (1)	DOP2013000191A (2)
EA (1)	EA024170B1 (2)
EC (1)	ECSP13012891A (2)
ES (1)	ES2594409T3 (2)
GE (1)	GEP20156318B (2)
GT (1)	GT201300207A (2)
HR (1)	HRP20161481T1 (2)
HU (1)	HUE030659T2 (2)
IL (1)	IL228052A (2)
LT (1)	LT2678327T (2)
MA (1)	MA34957B1 (2)
MX (1)	MX343788B (2)
NI (1)	NI201300072A (2)
PE (1)	PE20140703A1 (2)
PH (1)	PH12013501727A1 (2)
PL (1)	PL2678327T3 (2)
RS (1)	RS55433B1 (2)
SG (1)	SG192625A1 (2)
SI (1)	SI2678327T1 (2)
SM (1)	SMT201600409B (2)
WO (1)	WO2012114285A1 (2)
ZA (1)	ZA201306223B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA024170B1 (ru)	2011-02-23	2016-08-31	Люпин Лимитед	ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7
EP2822946A1 (en)	2012-03-06	2015-01-14	Lupin Limited	Thiazole derivatives as alpha 7 nachr modulators
PL2900675T3 (pl) *	2012-09-28	2019-08-30	Takeda Pharmaceutical Company Limited	Sposób wytwarzania pochodnej tienopirymidyny
US20150299178A1 (en)	2012-11-12	2015-10-22	Lupin Limited	Thiazole Derivatives as Alpha 7 NACHR Modulators
US9617211B2 (en)	2013-01-16	2017-04-11	Lupin Limited	Pyrrole derivatives as alpha 7 nAChR modulators
AU2014229300A1 (en) *	2013-03-13	2015-06-11	Lupin Limited	Pyrrole derivatives as alpha 7 nAChR modulators
TW201446243A (zh)	2013-06-03	2014-12-16	Lupin Ltd	4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) *	2013-06-17	2015-12-17	Lupin Limited	Pyrrole derivatives as alpha 7 nAChR modulators
EP3623371A1 (en)	2014-12-16	2020-03-18	Axovant Sciences GmbH	Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN107847494A (zh)	2015-06-10	2018-03-27	阿考温特科学股份有限公司	作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
JP2018523707A (ja)	2015-08-12	2018-08-23	アクソバントサイエンシズゲーエムベーハー	α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
UA120571C2 (uk) *	2016-03-22	2019-12-26	Мерк Шарп Енд Дохме Корп.	Алостеричні модулятори нікотинових ацетилхолінових рецепторів
WO2019236957A1 (en) *	2018-06-07	2019-12-12	The Regents Of The University Of Michigan	Prc1 inhibitors and methods of treatment therewith
AU2019297402B2 (en) *	2018-07-05	2024-05-02	Bayer Aktiengesellschaft	Substituted thiophenecarboxamides and analogues as antibacterials agents
CA3145592A1 (en)	2019-07-03	2021-01-07	Bayer Aktiengesellschaft	Substituted thiophene carboxamides and derivatives thereof as microbicides
CN118496197A (zh)	2019-12-20	2024-08-16	拜耳公司	取代的噻吩甲酰胺、噻吩甲酸及其衍生物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3953596A (en)	1973-06-14	1976-04-27	Ici United States Inc.	8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5608082A (en)	1994-07-28	1997-03-04	Agouron Pharmaceuticals, Inc.	Compounds useful as antiproliferative agents and GARFT inhibitors
CA2301742C (en)	1997-09-12	2004-05-18	Richard Friesen	2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
WO2002016355A2 (en) *	2000-08-21	2002-02-28	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
WO2003064404A1 (en)	2002-02-01	2003-08-07	Dainippon Pharmaceutical Co., Ltd.	2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
US7202367B2 (en)	2002-05-31	2007-04-10	Rhodia Chimie	Process for arylating or vinylating or alkynating a nucleophilic compound
SE0201938D0 (sv)	2002-06-20	2002-06-20	Astrazeneca Ab	New process
DE10244810A1 (de)	2002-09-26	2004-04-08	Bayer Ag	Neue Morpholin-überbrückte Indazolderivate
US7129235B2 (en)	2003-07-11	2006-10-31	Abbott Laboratories	Amides useful for treating pain
US7442805B2 (en)	2003-09-25	2008-10-28	Wyeth	Substituted sulfonamide-indoles
GB0403038D0 (en)	2004-02-11	2004-03-17	Novartis Ag	Organic compounds
WO2005092843A1 (en)	2004-03-29	2005-10-06	Neurosearch A/S	Novel urea derivatives and their medical use
ITTO20040264A1 (it)	2004-04-28	2004-07-28	Rotta Res Lab Spa	Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista
US8470829B2 (en)	2004-09-09	2013-06-25	Chugai Seiyaku Kabushiki Kaisha	Imidazolidine derivative and use thereof
US20060142349A1 (en)	2004-12-23	2006-06-29	Pfizer Inc	Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
EP1866314B1 (en)	2005-02-16	2010-09-15	NeuroSearch A/S	Novel diazabicyclic aryl derivatives and their medical use
FR2885616B1 (fr)	2005-05-12	2007-06-22	Servier Lab	Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20090012127A1 (en) *	2005-06-29	2009-01-08	Astrazeneca Ab	Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators
US20070032531A1 (en)	2005-08-04	2007-02-08	Apogee Biotechnology Corporation	Sphingosine kinase inhibitors and methods of their use
AU2006290814B2 (en)	2005-09-13	2012-06-07	Janssen Pharmaceutica N.V.	2-aniline-4-aryl substituted thiazole derivatives
CA2640476A1 (en)	2006-02-03	2007-08-16	Eli Lilly And Company	Compounds and methods for modulating fx-receptors
EP1987029B1 (en)	2006-02-16	2010-01-13	Neurosearch A/S	Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands
JO3019B1 (ar)	2006-04-19	2016-09-05	Janssen Pharmaceutica Nv	ثلاثي مستبدل 4،2،1-ثلاثي زولات
CA2659762A1 (en)	2006-06-27	2008-01-03	Abbott Laboratories	Thiazoline and oxazoline derivatives and their methods of use
EP2041085A1 (en)	2006-06-27	2009-04-01	Abbott Laboratories	Pyrrole derivatives and their methods of use
AU2007318058A1 (en)	2006-11-02	2008-05-15	Merck Sharp & Dohme Corp.	Heterocyclyl-substituted anti-hypercholesterolemic compounds
US20080287479A1 (en)	2006-12-20	2008-11-20	Pfizer Inc	Inhibitors of serine palmitoyltransferase
WO2009019278A1 (en)	2007-08-08	2009-02-12	Neurosearch A/S	Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0718735D0 (en)	2007-09-25	2007-11-07	Prolysis Ltd	Antibacterial agents
MX2010003156A (es)	2007-10-04	2010-04-01	Hoffmann La Roche	Derivados de aril amida substituida con tetrazol y usos de los mismos.
ES2460897T3 (es)	2007-10-04	2014-05-14	F. Hoffmann-La Roche Ag	Derivados de ciclopropil aril amida y usos de los mismos
JO2784B1 (en)	2007-10-18	2014-03-15	شركة جانسين فارماسوتيكا ان. في	5,3,1 - Triazole substitute derivative
WO2009115547A1 (en)	2008-03-19	2009-09-24	Janssen Pharmaceutica Nv	Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators
US7786171B2 (en)	2008-04-04	2010-08-31	Abbott Laboratories	Amide derivatives as positive allosteric modulators and methods of use thereof
TW201004939A (en)	2008-04-17	2010-02-01	Glaxo Group Ltd	Novel compounds
AR071763A1 (es)	2008-05-09	2010-07-14	Janssen Pharmaceutica Nv	Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
WO2010083444A1 (en)	2009-01-15	2010-07-22	Anvyl, Llc	Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
WO2010120854A1 (en)	2009-04-15	2010-10-21	Glaxosmithkline Llc	Chemical compounds
US20120071469A1 (en)	2009-05-14	2012-03-22	Neurosearch A/S	Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators
JO3250B1 (ar)	2009-09-22	2018-09-16	Novartis Ag	إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
JO3078B1 (ar)	2009-11-27	2017-03-15	Janssen Pharmaceutica Nv	مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
KR20140041442A (ko)	2011-02-03	2014-04-04	루핀 리미티드	알파 7 ｎａｃｈｒ의 조절자로 사용된 피롤 유도체
EA024170B1 (ru)	2011-02-23	2016-08-31	Люпин Лимитед	ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7
EP2691368A1 (en)	2011-03-31	2014-02-05	Lupin Limited	Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
EP2729455B1 (en)	2011-07-05	2016-09-14	Lupin Limited	Biaryl derivatives as nachr modulators

2012
- 2012-02-22 EA EA201370184A patent/EA024170B1/ru not_active IP Right Cessation
- 2012-02-22 SG SG2013059431A patent/SG192625A1/en unknown
- 2012-02-22 HR HRP20161481TT patent/HRP20161481T1/hr unknown
- 2012-02-22 SI SI201230775A patent/SI2678327T1/sl unknown
- 2012-02-22 AU AU2012221800A patent/AU2012221800B2/en not_active Ceased
- 2012-02-22 MA MA36224A patent/MA34957B1/fr unknown
- 2012-02-22 EP EP12709965.3A patent/EP2678327B9/en active Active
- 2012-02-22 BR BR112013021602A patent/BR112013021602A2/pt not_active IP Right Cessation
- 2012-02-22 AP AP2013007121A patent/AP3649A/xx active
- 2012-02-22 CA CA2826792A patent/CA2826792A1/en not_active Abandoned
- 2012-02-22 US US14/000,829 patent/US9072731B2/en not_active Expired - Fee Related
- 2012-02-22 RS RS20160972A patent/RS55433B1/sr unknown
- 2012-02-22 HU HUE12709965A patent/HUE030659T2/hu unknown
- 2012-02-22 DK DK12709965.3T patent/DK2678327T3/en active
- 2012-02-22 JP JP2013554966A patent/JP6118270B2/ja active Active
- 2012-02-22 LT LTEP12709965.3T patent/LT2678327T/lt unknown
- 2012-02-22 PE PE2013001969A patent/PE20140703A1/es not_active Application Discontinuation
- 2012-02-22 GE GEAP201213238A patent/GEP20156318B/en unknown
- 2012-02-22 MX MX2013009709A patent/MX343788B/es active IP Right Grant
- 2012-02-22 PL PL12709965T patent/PL2678327T3/pl unknown
- 2012-02-22 CN CN201280010409.0A patent/CN103402994B/zh not_active Expired - Fee Related
- 2012-02-22 PH PH1/2013/501727A patent/PH12013501727A1/en unknown
- 2012-02-22 KR KR1020137023970A patent/KR20140026378A/ko not_active Ceased
- 2012-02-22 ES ES12709965.3T patent/ES2594409T3/es active Active
- 2012-02-22 WO PCT/IB2012/050806 patent/WO2012114285A1/en not_active Ceased
- 2012-02-22 CU CUP2013000116A patent/CU24177B1/es active IP Right Grant
2013
- 2013-08-19 ZA ZA2013/06223A patent/ZA201306223B/en unknown
- 2013-08-21 IL IL228052A patent/IL228052A/en not_active IP Right Cessation
- 2013-08-22 GT GT201300207A patent/GT201300207A/es unknown
- 2013-08-23 CL CL2013002449A patent/CL2013002449A1/es unknown
- 2013-08-23 DO DO2013000191A patent/DOP2013000191A/es unknown
- 2013-08-23 NI NI201300072A patent/NI201300072A/es unknown
- 2013-08-27 CR CR20130415A patent/CR20130415A/es unknown
- 2013-09-13 CO CO13218508A patent/CO6761374A2/es unknown
- 2013-09-20 EC ECSP13012891 patent/ECSP13012891A/es unknown
2015
- 2015-05-06 US US14/705,144 patent/US9393247B2/en not_active Expired - Fee Related
2016
- 2016-10-19 CY CY20161101057T patent/CY1118107T1/el unknown
- 2016-11-11 SM SM201600409T patent/SMT201600409B/it unknown

Publication	Publication Date	Title
JP2014506590A5 (2)	2015-04-09
HRP20161481T1 (hr)	2016-12-30	Derivati heteroarila kao modulatori nachr alfa7
JP2010513444A5 (2)	2011-02-10
RU2002118302A (ru)	2004-04-20	Новые биарилкарбоксамиды
JP2006507241A5 (2)	2006-09-14
JP2003523342A5 (2)	2005-08-25
JP2014526435A5 (2)	2015-10-29
JP2006502112A5 (2)	2006-08-24
JP2017533968A5 (2)	2018-12-13
RU2012134306A (ru)	2014-02-27	Азотосодержащие производные гетероарилов
JP2005539030A5 (2)	2006-07-20
JP2017505762A5 (2)	2017-12-21
RU2017121044A (ru)	2018-12-17	Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2018102449A (ru)	2019-07-24	Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии
KR940013507A (ko)	1994-07-15	아릴 치환 헤테로사이클릭 화합물
JP2015506382A5 (2)	2016-11-24
JP2020502092A5 (2)	2021-01-21
JP2013509392A5 (2)	2013-11-28
RU2011105151A (ru)	2012-08-20	Азольные соединения
JP2018524338A5 (2)	2019-07-25
JP2019505595A5 (2)	2020-03-26
RU2018131766A (ru)	2020-03-20	6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
JP2014516070A5 (2)	2015-07-23
RU2015116816A (ru)	2016-11-27	Производное имидазола
JP2017520530A5 (2)	2018-06-28